Global New Psychoactive Substance Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global New Psychoactive Substance Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
New Psychoactive Substance report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global New Psychoactive Substance market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Cancer and Neuropathic Disorders are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for New Psychoactive Substance industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, New Psychoactive Substance key companies include Zynerba Pharmaceuticals, GW Pharmaceuticals, Teewinot Life Sciences, AusCann, Cannabics Pharmaceuticals, Tilray, Cyrelian, Anandia Laboratories and InMed Pharmaceuticals, etc. Zynerba Pharmaceuticals, GW Pharmaceuticals, Teewinot Life Sciences are top 3 players and held % share in total in 2022.
New Psychoactive Substance can be divided into Stimulants, Cannabinoids, Hallucinogens and Depressants, etc. Stimulants is the mainstream product in the market, accounting for % share globally in 2022.
New Psychoactive Substance is widely used in various fields, such as Cancer, Neuropathic Disorders, Spasticity and Others, etc. Cancer provides greatest supports to the New Psychoactive Substance industry development. In 2022, global % share of New Psychoactive Substance went into Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global New Psychoactive Substance market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Zynerba Pharmaceuticals
GW Pharmaceuticals
Teewinot Life Sciences
AusCann
Cannabics Pharmaceuticals
Tilray
Cyrelian
Anandia Laboratories
InMed Pharmaceuticals
Renew Biopharma
Cronos Group
ICC International Cannabis
Biotii Technologies
Segment by Type
Stimulants
Cannabinoids
Hallucinogens
Depressants
Cancer
Neuropathic Disorders
Spasticity
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the New Psychoactive Substance market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, New Psychoactive Substance introduction, etc. New Psychoactive Substance Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of New Psychoactive Substance market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
North America, Europe and Asia Pacific are the key regions for New Psychoactive Substance industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, New Psychoactive Substance key companies include Zynerba Pharmaceuticals, GW Pharmaceuticals, Teewinot Life Sciences, AusCann, Cannabics Pharmaceuticals, Tilray, Cyrelian, Anandia Laboratories and InMed Pharmaceuticals, etc. Zynerba Pharmaceuticals, GW Pharmaceuticals, Teewinot Life Sciences are top 3 players and held % share in total in 2022.
New Psychoactive Substance can be divided into Stimulants, Cannabinoids, Hallucinogens and Depressants, etc. Stimulants is the mainstream product in the market, accounting for % share globally in 2022.
New Psychoactive Substance is widely used in various fields, such as Cancer, Neuropathic Disorders, Spasticity and Others, etc. Cancer provides greatest supports to the New Psychoactive Substance industry development. In 2022, global % share of New Psychoactive Substance went into Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global New Psychoactive Substance market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Zynerba Pharmaceuticals
GW Pharmaceuticals
Teewinot Life Sciences
AusCann
Cannabics Pharmaceuticals
Tilray
Cyrelian
Anandia Laboratories
InMed Pharmaceuticals
Renew Biopharma
Cronos Group
ICC International Cannabis
Biotii Technologies
Segment by Type
Stimulants
Cannabinoids
Hallucinogens
Depressants
Segment by Application
Cancer
Neuropathic Disorders
Spasticity
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the New Psychoactive Substance market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, New Psychoactive Substance introduction, etc. New Psychoactive Substance Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of New Psychoactive Substance market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.